Specialty Supply
Inter-Pharma structures B2B sourcing enquiries for exceptional supply situations. Product status, target country, professional roles, lawful route and realistic availability are reviewed before any implementation.
Discuss your project →Inter-Pharma expertise
The exact product, authorisation status, target market, prescription or named-patient need, quantity and requesting professional party are captured first. Named-patient pathways are kept distinct from routine wholesale, parallel-import and market-launch routes.
A review starts with active substance and trade name, strength, dosage form, pack, origin and destination countries, authorisation status, required quantity, timing, patient-specific prescription or clinical rationale, and the requesting professional party. Temperature or dangerous-goods requirements and possible authorised alternatives are recorded before sourcing. Finding a product is not itself a legal, clinical or supply approval.
There is no single importation route for all European markets. Origin, destination, authorisation status, prescription, wholesale and import roles, authorised recipient, GDP transport and accountable release are assessed separately for each case. Inter-Pharma structures this review and the documented supply chain without promising a blanket legal route or product availability.
The applicable national named-patient, import, wholesale, pharmacy and prescribing route is identified for the specific destination. Authorisations, source, product identity, commercial feasibility, GDP transport and the accountable release decision are evidenced separately; no Europe-wide shortcut or availability guarantee is implied.
Potential sources are checked for authorisation, traceable provenance and product status. Batch, expiry, temperature, transport and documentation requirements are clarified before an offer or execution; availability is assessed case by case and is not promised.
The workflow links a complete case brief, regulatory assessment, source verification, commercial and logistical feasibility, documented approval and traceable handover. Responsibilities of manufacturer, wholesaler, pharmacy, prescriber, logistics provider and Inter-Pharma remain explicit.
This page is addressed to professional market participants and does not advertise specific unlicensed medicines. Applicable national medicines and advertising rules must be reviewed for each target country and case.
This page directly addresses the following professional and commercial searches:
Named Patient Supply Europe is relevant when product, regulatory status, temperature, volume, recipients, target markets and required process steps need to be assessed together. Inter-Pharma confirms the exact scope only after this project review.
At minimum, provide product type and status, temperature range, average and maximum stock, SKU and movements, recipients and destination countries, requested start, interfaces and additional services.
We structure your needs and connect the right partners and processes.